Actualizado 28/07/2006 18:27
- Comunicado -

In the Interests of Patients, Roche Will Consider all Options Following CHMP Opinion on Tarceva in Pancreatic Cancer (y

1. Steward, B W and Kleihues, P. 2003. World Cancer Report. World Health Organisation and the International Agency for Research on Cancer, IARC Press/Lyon, p248

2. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A Phase III trial of the National Cancer Institute of Canada Clinical Trials Group [NCIC-CTG]. (Abstract #1, ASCO 2005)

3. De Braud F, Cascinu S, Gatta G. 2004, May. Cancer of Pancreas. Critical reviews in oncology/hematology, 50(2):147-55

4. Truninger K (ed). 2002, Aug. Risk groups for pancreatic and bile duct carcinomas. Schweizerische Rundschau fur Medizin Praxis, 17;89 (33):1299-304

Roche Group Media Office: Phone: +41-61-688-8888 / e-mail: basel.mediaoffice@roche.com - Baschi Durr - Alexander Klauser - Daniel Piller (Head of Roche Group Media Office) - Katja Prowald (Head of R&D Communications) - Martina Rupp

Contenido patrocinado